Medicare’s Unprecedented Alzheimer’s Drug Decision

<p>Last week, Medicare took an unprecedented step to restrict patients’ access to the first new Alzheimer’s disease treatment in nearly 20 years. We talk with a doctor, a patient and a former federal official about this unusual move and its wide-ranging implications.</p><br><p>Guests:</p><p><a href="https://www.jayreinstein.com/#about" rel="noopener noreferrer" target="_blank">Jay Reinstein</a>, Alzheimer’s disease patient and advocate</p><p><a href="https://profiles.stanford.edu/sharon-sha" rel="noopener noreferrer" target="_blank">Sharon Sha</a>, MD, MS, Clinical Associate Professor of Neurology and Neurological Sciences, Stanford University</p><p><a href="https://cevr.tuftsmedicalcenter.org/news/2020/sean-tunis" rel="noopener noreferrer" target="_blank">Sean Tunis</a>, MD, MSc, Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health, former FDA advisor and former CMS official</p><br><p>Read a full transcript and dig deeper into the issues explored in today's episode <a href="https://tradeoffs.org/2022/01/20/medicare-alzheimers-drug-aducanumab/" rel="noopener noreferrer" target="_blank">on our website</a>.</p><br><p>Support this type of journalism today by <a href="https://tradeoffs.org/donate" rel="noopener noreferrer" target="_blank">making a donation</a>.</p><br><p><a href="https://open.acast.com/shows/61435631f581aac8b8520e65/episodes/bit.ly/tradeoffsnewsletter" rel="noopener noreferrer" target="_blank">Sign up for our weekly newsletter</a> to see what research health policy experts are reading right now, plus recommendations from our staff.</p><br><p>Follow us on <a href="https://twitter.com/tradeoffspod" rel="noopener noreferrer" target="_blank">Twitter</a>.</p><br /><hr><p style='color:grey; font-size:0.75em;'> See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for privacy and opt-out information.</p>